Variably protease-sensitive prionopathy in the context of a complex proteinopathy: clinical and neuropathological challenges
Related Experiment Video
Updated: Oct 31, 2026

Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans
Published on: January 8, 2015
Anika Simonovska Serra1,2, Claudia Marina Vargiu3, Sigrid Klotz2,4
1Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, and Austrian Reference Center for Human Prion Diseases (OERPE), Vienna, Austria.
Abstract:
Variably protease-sensitive prionopathy (VPSPr) is the most recently identified sporadic human prion disease, displaying distinctive clinical and neuropathological features and a unique western blot profile. Clinically, it frequently presents with longer disease duration than classic sporadic Creutzfeldt-Jakob disease (sCJD), neuropathologically with characteristic prion protein (PrP) deposition patterns, and biochemically with variable resistance of PrP Sc to proteinase K (PK) digestion. Here, we describe clinico-pathological features of two new patients with VPSPr identified at postmortem examination, review current literature, and emphasize diagnostic challenges when combined with other neurodegenerative conditions. As in sCJD, the polymorphism M/V at codon 129 of the PRNP gene influences the phenotypic expression, which includes features within the frontotemporal lobar degeneration and motor neuron disease (FTLD-MND) spectrum. Genetic and molecular analysis, as well as postmortem neuropathological examination and western blotting (case 2) were performed. Case 1 with an MM genotype showed a prominent involvement of the motor cortex and striatum, consistent with the pyramidal and extrapyramidal clinical symptoms. The cerebellum was devoid of PrP deposits. Co-pathologies including tau pathology consistent with argyrophilic grain disease (AGD) and limbic-predominant age-related TDP-43 encephalopathy (LATE) were detected as well. Case 2 with a VV genotype displayed a prominent involvement of the cerebellum with microplaques and a slightly different PrP staining pattern, compared to case 1. Both patients showed a prolonged disease duration, 7 years and 3.5 years, respectively. The clinical and neuropathological diagnosis of VPSPr remains challenging, especially in the presence of co-pathologies. The codon 129 M/V polymorphism modulates the clinic and/or pathological phenotypic expression of VPSPr within the FT(L)D-MND spectrum.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Parkinson Disease ll: Pathophysiology
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Subviral Agents

